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Freezing and lysis of erythrocytes in fluoridated blood were 
asse~sed as more effective ways of preserving glucose in blood 
samples. As a pre-requisite, it was necessary to measure glucose 
in haemolysate reliably. 
The YSI 23 AM glucose analyser was shown to measure glucose 
in haemolysate reliably without prior adaptation. An analytical 
coefficient of variation of 1.2% was achieved. There was excel-
lent agreement between glucose results for whole blood measured 
immediately and haemolysate prepared from whole blood after 
freezing for up to 24 h demonstrating that freezing is an effec-
tive way of preserving glucose in fluoridated blood samples. 
An attempt was made to develop an automated hexokinase 
method for glucose in haemolysate on the Cobas Mira analyser, but 
failed due to the presence of a significant negative interference 
which was haematocrit-dependent. 
There was an apparent delay of at least 1 h before NaF 
exerts its antiglycolytic action in whole blood resulting in an 
obligatory glucose loss of about 0.4 mmol/L. In studying the 
stability of glucose in haemolysate, - it was found that glucose 
remained stable for ~t least 1 day after an initial drop of about 
0.5 mmol/L. Addition of NaF (2 - 12 g/L) resulted in only a 
slight improvement. It was concluded that lysis of erythrocytes 
has a preservative effect on glucose in blood sample and that the 
delayed effect of NaF in whole blood was not due to slow penetra-
tion into erythrocytes. 
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2. INTRODUCTION: 
Blood glucose measurement, the cornerstone in the diagnosis 
and management of hyper- and hypoglycaemic disorders, is amongst 
the most frequently performed determinations in clinical biochem-
istry (1). Although it has been measured for over a century (2), 
and generations of refinement have been made to the methodology 
itself (1,2), the major flaw in the measurement of blood glucose 
,is pre-analytical, namely, glycolytic loss on standing and stor-
age (2). Consequently, misinterpretation of ' glucose results ' 
might occur (2,3,4). 
2.1 GLYCOLYSIS: MAGNITUDE OF THE PROBLEM 
The concentration of glucose in unpreserved blood sample 
will decrease significantly after collection due to glycolysis 
wi thin erythrocytes and ,-leucocytes (5,6). 
Blood qlucose fall by approximately 4-8% after 1 h, 6-13% 
after 2 hand 18-28% after 4 h at room temperature (7-10). 
2.2 GLYCOLYSIS INDIVIDUAL VARIATIONS 
The loss of glucose will be complicated by qualitative and 
quantitative differences in erythrocytes, leucocytes and the aqe 
of patient from whom blood is derived. ' 
2.2.1 Erythrocyte 
The rate of glycolysis is related to the haematocrit and the 
degree of qlycolytic enzyme activity. The higher the haemato-
crit, the higher the rate of glycolytic loss (8). Besides, accel-
2 -
erated in-vitro metabolism of blood glucose was shown in patients 
with polycythemia vera in whom high degree of glycolytic enzyme 
activity have been shown in the erythrocytes (11,12). 
2.2.2 Leucocyte ~ 
Under normal circumstances the contribution of leucocytes is 
probably negligible (8). However, leucocytosis greatly acceler-
ate the in-vitro metabolism of blood glucose (13). Severe spuri-
ous hypoglycae~ia has been shown to occur in some cases of leu-
kaemic leucocytosis despite the presence of fluoride (14~16). 
2.2.3 Age of individual 
In general, the decrease of blood glucose in unpreserved 
. samples from infants is significantly greater than in adults 
(17). It is even more dramatic for premature infants, the rate 
of loss is apparently about 8 times greater during . the first 
hour, and about 4 - 5 times greater in 2 h, than in adults (18). 
It is of interest to note that the high rate of glycolysis in 
erythrocytes of the newborn persist in some individuals (19). · 
For any haematocrit, specimens from adults contain more 
cells because newborns have cells with a larger mean cell volume. 
This emphasizes even further the more rapid glucose consumption 
by erythrocytes from infants against those from adults (8). 
2.3 METHODS OF BLOOD GLUCOSE PRESERVATION 
Ideally, samples for blood glucose measurement should be 
processed and analysed without delay. However, it is often 
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impractical or impossible in busy laboratories where several 
hours may elapse between specimen collection and laboratory 
processinq. Even lonqer time may elapse when specimens are 
mailed to central laboratories some distance from the hospital or 
doctors' offices where specimens were collected. Therefore, some 
form of preservation is mandatory. 
Glycolytic loss of blood qlucose can be minimised by various 
procedures but each has its own shortcominqs. The use of protein 
precipitants requires the precise samplinq of blood and protein 
precipitants (e.q. perchloric acid) near tbe patient by trained 
personel which is often impractical. Similarly, rapid plasma or 
serum separation from cells requires availability of a centrifuqe 
and possibly extra personnel. Coolinq is a simple way of pre-
servinq qlucose but not widely practised. Therefore, the usual 
practice is to use chemical preservatives such as NaF. Ideally, 
a chemical preservative should stop glycolysis instantaneously 
and have no interference with the measurement of blood qlucose, 
and preferably other analytes as well~ We have yet to recoqnise 
such an ideal preservative. 
2.3.1 Sodium fluoride (Na~) 
NaF inhibits qlycolysis by forminq an ionic complex with 
inorqanic phosphate and maqnesium ions, thereby interfering with 
the bindinq of ~nolase to its substrate (20). NaF, the most 
popularantiqlycolytic used (21), is reportedly the best preserv-
ative (22) 'available for ' blood qlucose estimation. Nonetheless, 
opinions differ as to how effective it is. Some early studies 
(23,24) reported that qlucose in fluoridated blood remains stable 
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for up to 10 days at room temperature. Sanders and Deadman (25) 
recently reported that NaF was able to preserve whole blood for 
48 h and that the drop in plasma glucose on standing might be 
ascribable to the osmotic shift of water out of erythrocytes with 
subsequent dilution of plasma glucose. Their claim was supported 
by data from Davies and Williams (26). Although the efficacy of 
NaF in preserving blood glucose appeared to be established by 
these groups, there is now ample evidence to suggest the contrary 
i.e. the antiglycolytic effect of NaF is incomplete 
(2,4,6,7,9,10,27). 
Recently, a most comprehensive study on the time course of 
changes of glucose in fluoridated blood by Chan et al (9) has 
clearly demonstrated that despite the presence of NaF (lg/L), 
blood glucose (both whole blood and plasma) decreased with time. 
The major fall occurred in the first hour; the rate of fall 
paralleled that of unpreserved heparinised blood. Thereafter, 
the rate of fall was much smaller indicating that NaF was , taking 
.effect. However, it was not until 4 h later that NaF inhibited 
glycolysis completely with a subsequent stabilisation of blood 
glucose concentration for at least 3 days. In effect, the loss 
of blood glucose was ' 4.4% at 1 h, 6.2% at 2 hand 7.1% at 4 h. 
In another study, Chan et al (27), studied the stability of 
blood glucose in various concentrations of NaF (up to 12 g/L 
blood). Their results showed that glucose loss is unavoidable 
irrespective of NaF concentration, though the loss was less with 
increasing NaF concentration. Thus, the loss of blood glucose 
depends on the concentration ' of NaF in the specimen and the time 
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lapse between specimen collection and analysis or plasma separa-
tion. These sources of variation may significantly affect the 
interpretation of results, particularly in newborns, some leu-
kaemics, and polycythemic patients as well as in adults who are 
'strong glycolysers'. This study further confirms previous 
~ 
reports that the inhibition of glycolysis by NaF is incomplete. 
2.3.1.1 Delayed effectiveness of NaF : clinical implications 
(i) Oral glucose tolerance test (OGTT) 
The clinical implication of a delayed effectiveness of NaF 
has recently been evaluated by Chan et al (3) in the context of 
OGTT. 
Of a hundred patients undergoing OGTT, 4 patients with im-
paired glucose tolerance (IGT) were misclassified as normal using 
the WHO criteria (28). Using the NDDG criteria (29), 7 patients 
. had discordant classifications between the two sets of . results. 
In these 7 patients, 5 IGT patients were misclassified as non~ 
diagnostic' whereas 2 'non-diagnostic' patients were misclassi-
fied as normal. In this study, no patient with diabetes was 
misclassified as IGT~ However, since completing the study, 2 
diabetic patients were misclassified as IGT. 
The findings of this study are particular relevant in the 
context of an epidemiological settinq where a large number of 
subjects are to be examined and single testing preferred in order 
to maximise voluntary cooperation. 
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(ii) Hypoglycaemia 
In 2 studies, De Pasqua et al (4) and Francis et al (30) 
showed that the absolute fall of glucose in fluoridated blood was 
similar throughout the range of blood glucose levels which means 
that the percenta~e glucose underestimated is greatest in the 
hypoglycaemic to normoglycaemic range. Moreover there was marked 
variation between samples, some falling much more than others. 
Although in the individual patient the glucose loss may he small 
and unlikely to affect clinical decisions, hypoglycaemia in 
someone whose true blood glucose level is merely at the low 
normal range could lead to unnecessary inve~tigation (4). This 
is particularly relevant in newborns and premature infants in 
whom the rate of glycolysis is much higher as well as in some 
adults who are 'strong glycolysers' (7). This is further accen-
tuated in some cases of leukaemic leucocytosis and polycythaemia 
vera (12-16). 
2.3.2 D-Mannose 
Mannose, first ' introduced in 1987 by Nakashima et 
was claimed to be a better antiglycblytic than NaF. 
phosphorylated to form mannose-6-phosphate, D-mannose 





cose) and third step (phosphorylation of fructose-6-phosphate) of 
glycolysis (32). 
In th~ir report, Nakashima et al studied the ability of D-
mannose to preserve blood glucose for up to S' h and showed that 
the rate of decrease of glucose in D-mannose (3 g/L) preserved 
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blood was lower than that of NaF (2.5 g/L) preserved blood. 
Their findings seemed to be supported by data from Liss et al 
(33) • 
Moreover, D-mannose was found not to interfere with most 
routine biochemical tests except creatine kinase assays involving 
hexokinase and Oglucose-6-phosphate dehydrogenase. But interest-
inqly, they claimed that D-m~nnose does not interfere with qlu-
cose measurements based on the hexokinase reaction. 
Despite these early reports favouring the use of D-mannose, 
recent evidence byChan et al (34) cast doubt on their early 
optimism. They studied the stability of plasma glucose in blood 
preserved with D-mannose (3 g/L blood), NaF (6 g/L blood) and a 
combination of both for 24 h and found that plasma glucose in D-
mannose preserved blood decreases progressively with time for at 
least 24 h (mean loss> 25%). In marked contrast, following an 
initial decrease, plasma glucose in fluoridated blood was stabi-
lised and the mean loss was about 06%. Nevertheless, a combina~ 
tion of fluoride and D-mannose was shown to be more effective 
than either alone. In the first 2 h, the decrease was 0.22 
mmol/L (3% loss) but thereafter, the decrease was arrested. 
This study showed that D-mannose alone is unreliable. The 
' mechanism accounting for the incomplete antiglycolysis is not 
clear but it might be due to continued metabolism of mannose-6-
phosphate to ° fructose-6-phosphate resulting in a progressive 
decrease of mannose (35). 
In another experiment, Chan et al found that plasma glucose 
in mannose~preserved blood actually increased initially (for the 
first 30 min) and then decreased. The initial increase might be 
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ascribable to a very rapid heteroexchange of intracellular glu-
cose with extracellular D-mannose (36). Thus, spurious elevation 
of plasma glucose would result if plasma glucose is measured in 
such a time frame. 
In contrast to the report by Nakashima et aI, Chan et al 
found that samples treated with D-mannose are not suitable for 
measurement of plasma potassium as it causes serious overestima-
tion of plasma potassium upon prolonged storage. This is not 
unreasonable since inhibitors of glycolytic pathway are known to 
reduce the activity of sodium pump with consequent pseudohyperka-
laemia (37). They also found that there is a tendency for man-
nose-preserved blood to haemolyse. Therefore, the suitability of 
mannose-preserved blood for other analysis is also questionable. 
Despite Nakashima's report that p-mannose does not interfere 
with glucose measurements, recent evidence suggest that it does 
interfere with a variety of methods the magnitude of which is 
dependent on the concentration and purity of mannose (38,39), the 
methodology (1,38,39) and" instrument used for glucose measurement 
(40) . 
2.3.3 Citric acid 
In 1988,Uchida et al (10) introduced what they called a 
"prompt glycolytic inhibitor" which is a granuloform mixture of 
citric acid,trisodium citrate,EDTA-2Na and NaF in the ratio of 
" 3.4:1r6:4.8:0.2 ;the dosage used is 10 g/L blood. 
The active ingredient in this glycolytic inhibitor is citric 
acid. Trisodium citrate was added to improve buffering. EDTA is 
9 
a chelating agent that acts as an anticoagulant. A minimal amount 
of NaF was added to help maintain glycolysis inhibition for an 
extended period of time. 
The rationale behind the use of this formulation is that 
citric acid is a pH adjuster that maintains blood pH at a non-
physiologic range level of 5.3 - 5.9 (intracellular pH ca. 
6.0). As the optimal pH levels of the various erythrocyte glyco-
lytic enzymes is known to be about 8.0 (41), maintenance at pH 
5.3 - 5.9 inhibits all glycolytic enzymes particularly hexokinase 
and phosphofructokinase as shown by measurements of various 
glycolytic intermediates. 
At the inhibitory pH at 25 C, the glucose concentration was 
shown to be stable over a peroid of 8 h but it did decrease by 
(0.07 + 0.06) mmol/L over 24 h showing that the prompt glycolytic 
inhibitor was extremely effective. 
This inhibitor was also shown to have no interference with 
the measurement of glucose using hexokinase, glucose dehydroge-
nase and glucose oxidase methods. 
To date,only the Uchida group has reported on the use of 
citric acid as an antiglycolytic.Therefore, the effectiveness of 
this inhibitor has yet to be fully evaluated. 
2.3.4 Cooling 
The rate of glycolysis decreases with temperature and cool-
ingblood samples on ice has been shown to effectively preserve 
blood gluc6se for at least 4 h from both adults and newborns 
(42) . This procedure of preserving glucose is simple and has 
received favourabl~ support from authorities in the field (6,43). 
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Des Pasqua et al (4) has reported that the storage of fluoridated 
blood in melting ice prevent most of the initial glucose loss 
observed at room temperature. Field and Williams (14) reported a 
patient with chronic lymphatic leukaemia whose blood glucose 
(fluoridated) dropped 25% but when refrigerated at 8 C, dropped 
only 10% in 2 h. Theoretically, the decrease can be further 
prevented by storing the blood samples frozen. This method of 
preserving blood glucose has yet to be fully explored . . 
2.3.5 Haemolysis 
All the reactions of glycolysis occur in the cytosolic 
compartment of the cell,where it is generally considered that the 
enzymes involved are in free solution and that the transfer of 
intermediates from one enzyme to the next occurs by diffusion 
(44). Disruption of the erythrocytes with subsequent dispersion 
of the enzymatic components may therefore enhance the stability 
of glucose in haemolysed blood.Early studies by Solomon et al 
(45) and Meites et al (18) seems to support this notion. They re-
ported that glucose in unpreserved haemolysate is more stable 
than that of whole blood although only changes over a short 
period were examined. 
this 
the 
The delayed effect of NaF is well documented. The reason for 
is unclear but may be due to slow penetration of NaF into 
erythrocytes (2). If this hypothesis pertains, it might be 
possible to accelerate the onset of action of NaF by lysing the 
erythrocytes thereby obviating the erythrocyte membrane barrier. 
This hypothesis is supported by a study of Schlebusch et al (46) 
who reported that glucose in haemolysate could be stable for 7 
days. Haemolysate was prepared by diluting 10 ul of whole blood 
with 1 ml of haemolysing solution containing digitonin as deter-
gent and maleinimide as enzyme inhibitor. However there was a 
slight decrease after 1 day and only 5 patients were studied. 
Nevertheless, this study raises the possibility that glucose in 
blood samples can be better preserved in the presence of NaF if 
the erythrocytes can be lysed by simple means, e.g. by the 
presence of a small amount of deterg~nt.ldeally, it should not 
involve dilution which adversely affects precision. 
2.4 AIMS OF THE PROJECT 
In this project, an attempt was made to achieve better 
methods of preserving blood glucose in NaF. To accomplish this, 
firstly, I explored whether freezing fluoridated blood immediate-
ly after collection could prevent glycolytic loss completely. 
Secondly, I tested the hypothesis that lysing the erythro-
cytes enhances the rate at which fluoride acts on its target 
glycolytic enzyme(s), by comparing the stability of glucose in 
whole blood with that in haemolysate, with and without the 
presence of NaF. Haemolysis can be effected by 'freeze and 
thaw' and preferably by detergents (triton X-lOO, saponin, SDS) 
if prov~d not to interfere with glucose measurements. 
However, the use of frozen and detergent-based samples means 
subsequent analysis of glucose in haemolysate. Therefore, as a 
pre-requisite, I attempted to establish methods for the measure-
ment of whole blood haemolysate glucose. 
Basically, glucose methods fall into 2 main categories: 
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chemical methods and enzymic methods (1). Chemical methods 
employing ferric reduction, cupric reduction, or aromatic amine 
condensation are non-specific and susceptible to a large number 
of interferents. The reduction of interferences usually require 
protein precipitation or dialysis which are not only time-consum-
ing, tedious, but also error-prone. Therefore they are now obso-
lete and largely superseded by specific enzymic methods, namely, 
the hexokinase method,the glucose oxidase method and the glucose 
dehydrogenase method. 
Available enzymic methods for measuring glucose concentra-
tion in haemolysates are not entirely satisfactory (47-49). 
Preparation of haemolysate, for both manual and automatic meth-
ods, requires dilution of a small blood sample (10 - 40 uL) by a 
relatively large volume of haemolyzing solution (1 mL). This 
introduces dilution factors of 25 - 100 which renders accurate 
measurement of glucose dependent on the precision of the dilution 
process. 
Therefore, I attempted to measure whole blood ha~molysate 
glucose (without prior dilution) in the YSI 23 AM glucose analy-
ser (based on the glucose oxidase method) and Cobas Bio and Cobas 
Mira employing the hexokinase method. 
The YSI model 23 AM glucose analyser (Yellow Spring Instru-
ment Co., Yellow Springs, USA) is amongst the most widely used 
glucose analysers requiring only a small sample volumn (25 uL) 
and being suitable for stat as well as batch analysis (2). 
Although it was not advertised as such, it is capable of 
qiving 'identical' results whether the erythrocyte are intact 
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(whole blood glucose) or lysed (haemolysate glucose) by 'freeze 
and thaw', hypotonic shock or treatment with detergent (private 
communication with manufacturer). Nevertheless, these claims 
have not been confirmed by any published data. To evaluate the 
feasibility of measuring haemolysate glucose using this instru-
~ 
ment, parallel analysis of whole blood and haemolysate for each 
sample were carried out. 
The Cobas Bio and Cobas Mira, a batch centrifugal analyser 
and a random access analyser respectively, are popular worldwide. 
The parameters of analysis are programmable with high flexibility 
in both analyser. Therefore, we attempted to adapt the hexoki-
nase method, reportedly the most specific enzymic glucose method 
() and an internationally reference method (40), to this instru-
ments. 
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3. MATERIALS AND METHODS 
3.1 EVALUATION OF THE YSI 23 AM GLUCOSE ANALYSER FOR GLUCOSE 
MEASUREMENT IN HAEMOLYSATE 
3.1.1 Principle of measurement 
The YSI 23 AM glucose analyser (Yellow Spring Instrument 
Co.; Yellow Springs, USA) employs a glucose oxidase method based 












--------~) gluconic acid + H 0 
22 
+ 
--------~) 2H + 0 +2e 
2 
--------~) 2H 0 - 4e 
2 
*GOX is glucose oxidase (EC 1.1.3.4) 
The heart of the measurement system is an electrode with a 
tip covered by a 3-layer membrane which serves both to protect 
the electrode and to ' define a diffusion path to them. 
Glucose in the vicinity of the probe diffuses through the 
membrane's outer layer and comes in contact with glucose oxidase 
immobilised on the second layer. At this point, reaction (i) 
takes place converting glucose to gluconic acid and hydrogen 
peroxide. The hydrogen peroxide in turn diffuses through the 
membrane's inner layer coming into contact with the platinum 
15 · 
anode where reaction (ii) takes place. The circuit is completed 
by a silver cathode where oxygen is reduced to water (reaction 
iii). Thus, the current produced is proportional to the quantity 
of hydrogen peroxide diffused and hence the glucose concentration 
in the sample. 
3.1.2 Preparation of haemolysate 
Haemolysate was prepared by 'freeze and thaw'. Blood sam-
ples were frozen by liquid nitrogen and stored at -70 C. They 
were then thawed within 24 h at room temperature for 15 minutes 
just before analysis. In our experience in the Chemical Patholo-
gy Lab of Prince of Wales Hospital , more than 90% of erythro-






patient blood samples collected in 1 ml screw-capped 
tubes (Sarstedt Ltd, Beaumont Ley Leicester, UK) were 
Whole blood glucose concentration was measured in 
duplicate and the sample frozen immediately. Haemolysates were 
then prepared as described . above. The concentration of glucose 
in the haemolysates was then measured in duplicate in the YSI 23 
AM glucose analyser according to the manufacturer's instructions. 
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3.2 DEVELOPMENT OF A GLUCOSE ASSAY IN HAEMOLYSATE IN COBAS BIO 
AND COBAS MIRA 
3.2.1 Glucose measurement -
Glucose was measured in the Cobas Bio and Cobas Mira analy-
sers using the Roche UNI-KIT which employs an end point hexoki-
nase method based on the following reactions 
HK* 




------------+) D-Gluconate-6-P + NADH + H 
* HK is hexokinase (EC 2.7.1.1) 
** G6P-DH is glucose-6-phosphate dehydrogenase (EC 1.1.1.49) 
The formation of NADH measured by the change in absorbance 
at 340 nm, is proportional to the amount of glucose present. 
3.2.2 Preparation of haemolysate 
Haemolysates were prepared by 'freeze and thaw'. Blood sam-
pIes were frozen at -70 Cfor 30 minutes and then thawed at room 
temperature for 20 minutes. The haemolysatewas then centrifuged _ 
at 10,000 rpm for 5 minutes. 
3.2.3 Cobas Bio 
3.2.3.1 Optimisation of sample size 
5 patient blood samples collected into 1 ml screw-capped 
fluoride tubes (Sarstedt Ltd, Beaumont Ley Leicester, UK) were 
IT 
haemolysed as described above. 
The resulting haemolysates were analysed in duplicate in the 
Cobas Bio with 2 instrument settings. The first was the Roche 
UNI-KIT recommended protocol (as listed in Table 1). The second 
was identical to the first except that the sample volume was 2 ul 
instead of 3 ul. Absorbance data (mean) were obtained for each 
sample (Table 2). 
18 
Table 1. Assay parameters of Cobas Bio for the measurement of 
glucose in haemolysate. 
1 Unit mmol/L 3 
2 Calculation factor 0 
3 Standard 1 conc. 10.8 
4 Standard 2 conc. ~ 16.5 
5 Standard 3 conc. 
6 Limit mmol/L 33 
7 Temperature C 37 
8 . Type of analysis 5 
9 Wavelength nm 340 
10 Sample volume ul 3 
11 Diluent volume ul 50 
12 Reagent volume ul 200 
13 Incubation time s 0 
14 Start reagent volume ul . 0 
15 Time of first reading s 0.5 
16 Time interval s 120 
17 Number of readings 2 
18 Blanking mode 1 
19 Printout mode 1 
19· 
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Table 2. Initial absorbance of 5 haemolysate samples as measured 
in the Cobas Bio using a sample size of 3 ul and 2 ul. 
Initial absorbance 
saml2le 3 ul saml2le 2 ul saml2le 
.~ 
1 4. 1545 3.6168 
2 4.0774 3.5689 
3 4.1364 3.6403 
4 4.2686 3.6000 
5 4.3234 3.6673 
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3.2.3.2 Discussion 
The instrument specification for spectrophotometer linearity 
at 340 nm is between 0 - 3 absorbance units. 
As can be seen from Table 2, using the recommended sample 
volume of 3 ul, th~ initial absorbance of aIlS samples was far 
too high. The linearity of the spectrophotometer was still 
exceeded even when the sample size was decreased to 2 ul. 
Since the Cobas Bio photometric system employs a longitudi-
nal light path, the sample blank can only be diminished by de-
creasing the sample volume but not reagent volume (50). This 
severely limits the use of neat haemolysate in this system. 
Therefore it is not feasible to use the Cobas Bio analyser for 
assaying haemolysate which has a very high sample blank at 340 nm 
largely due to the absorbance of haemoglobin (51). 
21 · 
3.2.4 Cobas Mira 
3.2.4.1 Optimisation of sample/reagent volume ratio 
10 patient blood samples collected into 1 ml screw-capped 
fluoride tubes (Sarstedt Ltd, Beaumont Ley Leichester, UK) were 
haemolysed as described. 
Using the R-S reaction mode, glucose concentration in the 
haemolysates was assayed in duplicate with each of 5 instrument 
settings, each differing from the others only by the sample to 
reagent volume ratio as designated (i) to (v) below . 
• 
Sam}2le Reagent SamI21e diluent SamI2le to total 
volume.ul volume)ul (water),ul volume ratio 
( i) 4 400 30 108 
(ii) 4 500 30 134 
(iii) 4 550 30 146 
(iv) 3 400 30 144 
(v) 3 500 30 178 
Apart from this, the instrument settings were those recom-
mended in the Roche UNI-KIT -instructions as listed in Table 3. 
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Table 3. Assay parameters of Cobas Mira for the measurement of 
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Number of steps .: 1 
Calc. step A .: endpoint 
Readings first T1 Last 10 
CALIBRATION 
Cal ib. interval 
Reagent blank 
Reag. range low 
high 
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Since the R-S reaction mode (Table 3) corresponds to one in 
which the hexokinase reagent, sample and diluent (distilled 
water)are pippetted in parallel to the cuvette, the initial ab-
sorbance reading designated T1 approximates the blank absorbance 
~ 
contributed by the sample and reagent. 
Among the 10 haemolysate samples, the maximum blank absorb-
ance contributed by the sample and reagent was obtained for each 
of the 5 sample/reagent volume ratio. 
Considering an upper linearity limit of 30 mmol/L glucose, 
the final absorbance can be calculated from the initial · absorb-
ance as well as the sensitivity of assay since 
Final absorbance 
= initial absorbance . + sensitivity x 30 mmol/L 
Therefore, the maximum initial absorbance and final absorb-
ance were obtained for each· of the 5 sample/reagent volume ratio 
(Table 4). 
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Table 4. Maximum initial and final absorbance among 10 haemoly-
sates as measured in the Cobas Mlra using 5 different sample/re-



































3 . 2 . 4 . 2 'D i s c u s s i on ' : 
Since the assay protocols (i) and (ii) resulted in final 
absorbance larger than 2.40 which is the upper linearity limit of 
absorbance for the photometric system in Cobas Mira, they were 
not considered. For sample reagent volume ratio designated (iii) 
~ 
and (iv), the final absorbance were relatively close to 2.40 and 
so would not be taken into consideration. Therefore, Cv) was 
selected which was a sample volume of 3 ul, sample diluent of 30 
ul and hexokinase reagent of 500 ul. This is in contrast to the 
Roche recommended sample size of 4 ul, sample diluent of 30 ul 
and hexokinase reagent of 200 ul which are intended for use with 
plasma or serum glucose. 
3.2.4.3 Optimisation of the assay protocol 
In the last section, sample and reagent volume Df 3 ul and 
500 ul respectively were selected but the precision of the assay 
for haemolysate glucose was poor. In fact, individual duplicates 
showed a discrepancy of up to 3 mmol/L. As indicated in Table 5, 
the mean within-run CV for 10 duplicates of haemolysate was 7.6% 
which was unacceptably high especially when compared to the 
analytical goal stated by Fraser (52). 
In contrast, the precision of plasma controls designated NC 
and AC was highly satisfactory showing that the poor precision of 
the haemolysate was not due to instrument problems. 
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Table 5. Within-run precision study of haemolysate and plasma 




(sample 3 ul , hexokinase reaqent 500 ul , sample diluent 
type Glucose, mmol/L 
n x SD CV 
Haemolysate 10 9.00 0.68 7.60% 
NC 
AC 
20 4.78 0.08 
20 16.56 0.30 
NC is Ciba-corning normal plasma control 




Examination of the haemolysate absorbance data revealed that 
the expected end-point had not been reached in general, but 
rather there was an upward or downward trend at the point of 
final absorbance. In addition, there was some 'staggering' of 
absorbance values tn between. Examples of the reaction profile 
for haemolysate and plasma is shown in Table 6. 
28 
Table 6. Reaction profiles of glucose in haemolysate and plasma 
as measured in the Cobas Mira using the R-S reaction mode. 
Analysis cycle Absorbances 
:::r 
Haemolysate 1 Haemolysate 2 Plasma control 
T1 1.0939 1.1483 0.1633 
1 1.1030 1.1705 0.1678 
2 1 . 3306 . 1.3933 0.2402 
3 1 .4378 1.5247 0.2578 
4 1.4816 1.5076 0.2611 
5 1.4700 1.5608 0.2607 
6 1.5273 1.6340 0.2614 
7 1.5528 1.6049 0.2615 
8 1.5679 1.6079 0.2610 
9 1.5306 1.6051 0.2615 
10 1.4999 1.6180 0.2615 
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For the plasma control, the change of absorbance values with 
time showed a typical reaction profile for endpoint reactions. 
In view of the reaction profile and the staggering of ab-
sorbance 'values, it was suspected that inadequate mixing of 
haemolysate in the cuvette was a major cause of imprecision. 
Another possibility which might add to the imprecision of the 
haemolysate assay could be the sampling inconsistency of viscous 
haemolysates. 
To improve mixing, another assay protocol involvin~ the use 
of a larger volume of sample diluent (92 ul) was considered in 
the hope that when haemolysate was dispensed into the cuvette, a 
larger volume of sample diluent would flush the haemolysate into 
the cuvette with better dispersion. In accordance with the 
change of diluent volume, the volume of hexokinase reagent was 
decreased to 430 ul. 
With a modified diluent and reagent volume, the 10 haemoly-
sate samples were reassayed as well as the plasma controls. The 
results are shown in Table 7. As can be seen, although there was 
a significant improvement in precision using the modified assay 
protocol, it still left much to be desired. Again, the reaction 
profiles for the haemolysate samples were similar to the previous 
assay protocol (sample 3 ul, hexokinase reagent 500 ul and sample 
diluent 30 ul) ~ 
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Table 7. Within-run precision study of haemolysate and plasma 
glucose as measured in the Cobas Mira using the R-S reaction 
mode. 
ul) 
(sample 3 ul , hexokinase reagent 430 ul , sample diluent 92 
Sample type Glucose, mmol/L 
n x SD 
Haemolysate 10 9.31 0.59 
NC 
AC 
20 5.01 0.07 
20 16.81 0.11 
NC is Ciba-Corning normal plasma control 







Since the above modification did not lead to elimination of 
the mixing problem, further changes were considered. Instead of 
employing the R-S reaction mode as recommended by Roche which 
involves the parallel pipetting of sample and hexokinase reagent 
to the cuvette, a ~ifferent reaction mode, the R-S-SR1 mode was 
used. In , this mode, the sample and primary reagent is pipetted 
in parallel to the cuvette. After a time lag, the starter re-
agent is dispensed to the cuvette and the reaction monitored. 
As the use of primary reagent was not app,licable in this 
single-reagent assay, distilled water was used instead. The 
starter reagent was the hexokinase reagent which was dispensed 
after a time lag, the magnitude of which was determined experi-
mentally. 
Using a prolonged incubation of haemolysate samples with 
distilled water before the addition of hexokinase reagent, it was 
found that a time lag of 13 analysis cycles, which corresponds to 
5.4 minutes, was sufficient to allow stabilisation of the haemo-
lysate absorbance. A further 11 analysis cycles after the addi-
tion the hexokinase reagent was adequate for the endpoint to be 
reached. 
Due to the limi,tation imposed upon the maximum volume (95 
ul) of the starter reagent which can be pipetted, the volume of 
hexokinase reagent pipetted has to be much smaller than in the 
R-S reaction mode. In accordance with this change, a 5-fold more 
concentrated , hexokinase reagent had to be reconstituted in order 
that a near maximum volume of 90 ul could be used. Consequently, 
the assay parameters as shown in Table 8 were used. 
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Table 8. Assay parameters of Cobas Mira for the measurement of 











Sample dil. name 
Post dil. factor 
cone. factor 
Sample 
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Vol: 340 ul 
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3.2.4.4 Evaluation of the RS-SR1 protocol 
Blood from a normal individual was collected into a 
tube (Bunzyl Medical & Lab Products, Hendon, 
10 ml 
South heparinised 
Australia). It was then incubated" at 37 C in a water bath for 2 
days so as to enhance glycolytic loss of blood glucose. Plasma 
glucose and whole blood glucose were found to be undetectable in 
an Astra-8 analyser (Beckman Instrument Inc., Brea, California, 
U.S.A.) and YSI 23 AM glucose analyser respectively. The blood 
sample was then haemolysed as described above. 
To 3 aliquots of 0.9 ml zero-glucose haemolysate (haemoly-
sate measured by SMI pipette), 0.1 ml of aqueous standard glucose 
solutions of 0, 60 and 120 mmol/L respectively were added. In 
effect, 0, 6, and 12 mmol/L of glucose was added. At each level, 
haemolysate glucose was assayed 10 times in the same run using 2 
assay protocols, the R-S and R-S-SR1 respectively. The within-
run precision and the mean recovery of glucose were then calcu-
lated (Table 9). 
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Table 9. Precision and recovery studies of glucose in haemoly-
sate using 2 reaction modes. 






b/ R-S mode 







(mean ± SD, n = 10) 
0.43 + 0.05 
4.79 ± 0.12 
10~46 + 0.14 
Glucose recovered£mmolLL 
(mean ± SD, n = 10) 
1.06 + 0.50 
5.86 + 0.86 










As can be seen from Table 9, the R-S-SRl protocol seemed to 
work much better with respect to precision. It further confirmed 
that the imprecision of the previous protocols was due to a 
mixing problem in the cuvette rather than sample aspiration 
inconsistency. Nevertheless, the recovery of glucose in haemoly-
sate was low, the mechanism of which has to be elucidated. But 
the presence of high concentration of intracellular components in 
haemolysate raises the suspicion that those of the blood cells 
particularly erythrocytes might be responsible. 
Therefore the next study was undertaken to investigate if 
there was any association between the haematological parameters 
such as red cell count, haemoglobin concentration, white cell 
count, platelet count with the recovery of glucose in haemoly-
sate. 
3.2.5 To study the effect of variations in haematological param-
eters on the recovery of glucose in haemolysate 
3.2.5.1 Procedure: Experiment (i) 
After completion of blood counting in a Cell-Dyn 1600 Multi-
Parameter Automated Haematology Analyser (Sequoia-Turner Corp., 
Mountain view, California, U.S.A.), 24 patient blood samples 
collected into EDTA tubes (Sherwood Medical, Sussex, UK) were 
incubated in a 37 C water bath for 2 days to .enhance glycolytic 
loss of blood glucose and the plasma glucose was found to be 
und~tectable in all samples as measured by Astra-8 analyser. The 
blood samples were then haemolysed as described previously. To 
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500 ul of each haemolysate, 50 ul of aqueous glucose standard (60 
mmol/L) was added. The spiked haemolysate was assayed in dupli-
cate with the R-S-SR1 protocol. 
Recovery of haemolysate glucose, defined by the ratio of 
mean glucose recovered to that added was then calculated for each 
· sample. 
The correlation between recovery and various haematological 
parameters, namely white count, red count, haemoglobin concentra-
tion, haemocrit and platelet count are shown in Table 10. The 
scatterplots are shown in Figures 1-4. 
As can be seen from Table 10 and Figures 1-4, there was a 
strong negative correlation between the recovery of haemolysate 
glucose and red cell count, haemoglobin concentration or haemato-
crit. On the other hand, although the correlation between the 
recovery and platelet count was significant, the association was 
relatively weak. Moreover, the range of recovery was wide span-
ning from about 30% to 80% (mean about 60%). 
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Table 10. Correlation (r) between recovery of glucose in haemo-
lysate and various haematological parameters in Experiment (i) 
Haematoloqical parameters Jl L ~ 
White cell coun~ 14 0.297 0.151 
Red cell count 14 -0.869 0.000 
Haemoglobin 24 -0.847 0.000 
Haematocrit 14 -0.872 0.000 
Platelet 14 -0.472 0.044 
p* refers to significance of correlation by 1 tailed paired 
t-test 
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Fig. 1. Correlation between recovery of glucose ln haemolysate 
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Fig. ' 2. Correlation between recovery of glucose in haemolysate 





>- 0.60 Cl::: 
w 
> 0.50 0 
U 







y = 1. 1237 - 0.01 62 x 
r =-0.872 , p< 0.001 
n =14 




40 45 50 . 
Fig. 3. Correlation between recovery of glucose in haemolysate 
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Fig. 4. Correlation between recovery of glucose ln haemolysate 
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3.2.5.1 Procedure Experiment (ii) 
In another study, after completion of blood counting in the 
Cell-Dyn haematological counter, 38 patient blood samples (EDTA 
blood) were frozen at -20 C for up to a week. The blood samples 
were then haemolysea. Glucose in haemolysates was assayed on the 
Cobas Mira analyser with the R-S-SR1 protocol and the YSI 23 AM 
glucose analyser. 'Recovery', here defined as the ratio of 
haemolysate glucose measured in the Cobas Mira analyser to that 
in YSI glucose analyser, was calculated. The associations be- . 
tween the 'recovery' and the haematoloqical parameters were 
assessed. As shown in Table 11 and Figures 5-7, there were 
significant negative correlations between 'recovery' with red 
cell count, haemoglobin concentration and haematocrit although 
the association were weaker than in the previous study. Besides, 
the mean 'recovery' (about 85%) was significantly higher whereas 
the range (about 80% - 98%) was narrower . . 
Presumably, the lower recovery in the previous study was 
related to the biochemical change which occured during in~ubation 
at 37 C leading to a greater interference in the assay, although ' 
this is largely speCUlative. 
Table ' 11. Correlation er) between 'recovery' of glucose in 




.n. ' L ~ 
White cell count 38 -0.093 0.290 
Red cell count 38 -0.443 0.002 
. Haemoglobin 38 -0.462 0.001 
Haematocrit 38 -0.490 0.000 
Platelet 38 -0.019 0.454 
p* refers to significance of correlation by 1 tailed paired 
t-test ' 
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Fig. 5. Correlation between recovery of glucose in haemolysate 
and haemoglobin concentration in Experiment Cii). 
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Fig. 6. Correlation between recovery of glucose in haemolysate 
and haematocrit in Experiment (ii). 
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Fig. 7. Correlation between recovery of glucose In haemolysate 
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3.2.5.2 Discussion 
These studies clearly showed that there was significant 
negative interference which was haematocrit-dependent and showed 
wide variability. The nature of interference should be clearly 
defined so that mea~ures can be considered for its prevention and 
subsequent elimination. 
It is well documented that haemolysis can cause interference 
by various mechanisms (51,53): 
Ca) . increase of intracellular constituents in extracellular 
fluid, e.g. lactate dehydrogenase. 
(b) optical interference by haemoglobin. 
(c) biochemical interference by intracellular constituents in 
reactions of the assay~ 
Ca) is irrelevant since the concentration of glucose in 
whole blood and haemolysateis the same. This was confirmed by 
the results on the evaluation of the YSI 23 AM glucose analyser. 
Cb) is unlikely to cause a negative interference on the assay. 
Judging from the reaction profile of the zero-glucose haemoly~ 
sate, there was ·an increase of absorbance after addition of the 
starter reagent hexokinase resulting in a positive interference 
of about 0.4 mmol/L. This was not due to residual glucose 
present after incubation at 37 C because zero glucose was con-
firmed in the whole blood and plasma before haemolysis. 
Biochemical interference by haemoglobin and other intracel-
lular constituents remains a possibility. The causal relation-
ship accounting for the inverse association between haemoglobin 
and glucose concentration, if any, can be established by an 
48 · 
interference experiment which involves the spiking of pure haemo-
globin standard to plasma of known glucose concentration. Unfor-
tunately, pure haemoglobin standard was not available and so 
their causal relationship could not be studied. 
As hyperviscosity will cause problems in automated systems 
<1# 
(54), it is possible that the high viscosity of the haemolysates 
could have contributed to the negative interference. 
There are 2 approaches to investigating whether hyperviscos-
ity, played a significant role. Firstly, the steps of the assay 
on ' the Cobas Mira can be simulated in a manual procedure. As the 
speed at which sample haemolysate is aspirated can be controlled 
to the point that 'short' sampling would not occur, the problem 
of hyperviscosity would be obviated in the manual procedure. 
However, given a limited amount of reagent and time, the larger 
volumes of hexokinase reagent required in a manual procedure and 
the tediousness render this approach impractical. Another ap-
proach involves the addition of detergents e.g. Triton X-lOO, 
saponin, or SDS to haemolysates. In the presence of these deter-
gents which act as surfactants, the fluidity of the haemolysate 
would be increased. 
To be used as surfactants, the detergents must not interfere 
with the assay. Since they would be concomitantly used to effect 
haemolysis, the detergents at various concentrations would need 
to be assessed for interference. 
It was previously found that 3% (v/v) Triton X-lOO, 2% (w/v) 
saponin or 1% (w/v) SDS can effectively haemolyse blood samples 
over a wide range of haematocrit within 10 minutes (unpublished 
data) . . The major drawback of Triton X-lOO is that complete 
dryness IS difficult to obtain so that when blood samples are 
added significant dilution is likely, particularly in small 
paediatric samples. Therefore only saponin and SDS were consid-
ered in this study. 
3.2.6 Interference study of saponin 
3.2.6.1 Procedure 
Glucose solutions of 6 mmol/L and 12 mmol/L were prepared in 
different concentrations of saponin solution (0 - 7%). They. were 
then assayed in duplicate . . 
3.2.6.2 Discussion 
As can be seen in Figure 8, there is a positive interference 
introduced by saponin which is proportional to its concentration. 
To elucidate whether saponin itself imparts the absorbance at 340 
nm or it potentiates the absorbance of NADH at 340 nm, 0 - 8% of 
saponin solutions (without glucose) were assayed. This is useful 
because any net change in absorbance is ascribable to saponin 
alone. As can be deduced from Figure 9, saponin actually imparts 
an absorbance at 340 nm. An apparent glucose concentration of 
1.3 mmol/L was contributed by each percent of saponin solution. 
Therefore, it is obvious that saponin is inappropiate. 
50 . 
Fig. 8. Interference of saponln at 6 mmol/L and 12 mmol/L glu-
cose. 
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Fig. 9. Interference of saponin at 0 mmol/L glucose. 
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3.2.7 Interference study of SDS 
3.2.7.1 Procedure 
Glucose solutions of6 mmol/L and 12 mmol/L were prepared in 
different concentrations of SDS solution (0 - 9%). They were 
then assayed in duplicate. 
3.2.7.2 Discussion 
As can be seen in Figure 10, there was an exponential in-
crease in negative interference when SDS was greater than about 
.1.5%. The negative interference was also dependent on the con-
centration of glucose. For the same SDS concentration, the error 
introduced was proportional to glucose concentration of the 
sampl~. Since in routine circumstances, the amount of blood 
added to sample collection tubes is so variable (particularly 
paediatric samples), it is unlikely that SDS can be used with a 
large safety margin, and so could not be considered for further 
study. 
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3.3. STABILITY OF GLUCOSE IN HAEMOLYSATE 
3.3.1 Preparation of haemolysate 
As describe in 2.1.2 
3.3.2 Glucose measurement 
Whole blood and haemolysate glucose measurements were per-
formed using the YSI 23 AM glucose analyser. 
3.3.3 Procedure 
3.3.3.1 Experiment (i) 
Blood samples were collected from 24 adults and aliquoted 
. into 2 pairs of 1 ml sc·rew-capped tubes; one pair containing NaF 
(2g/L blood)- and the other heparin. One tube from each pair was 
froz~n immediately in liquid nitrogen while blood glucose in the 
remaining tubes was measured immediately and after 1~ 2, 4, 8, 
and 24 h of storage at room temperature. Haemolysate was pre-
pared from the frozen samples and the glucose concentration was 
measured immediately and after 1, 2, 4, 8, and · 24 h of storage 
at room temperature. Therefore 4 sets of glucose results were 
obtained; WBF (whole blood glucose in fluoride tube), WBH (whole 
blood glucose in heparin tube), HF (haemolysate gl~cose in fluo-
ride tube) andHH (haemolysate glucose in heparin tube). 
3.3.3.2 Experiment (li) 
Blood samples were collected from 21 adults and aliquoted 
into 4 tubes, one containing heparin and the other three tubes 
containing NaF concentrations of 2 giL, 6 giL, 12 glL blood 
respectively. The blood samples were immediately frozen in 
liquid nitrogen andhaemolysate prepared. Glucose concentration 
in the resulting haemolysate was measured immediately and after 
55 . 
1, 2, 4,8, and 24 h of storage. Therefore 4 sets of glucose 
results were obtained; HH (haemolysate glucose in heparin tube), 
HF2 (haemolysate glucose in NaF, 2 g/L blood), HF6 (haemolysate 
qlucose in NaF, 6 g/L blood), HF12 (haemolysate glucose in NaF, 
~ 
12 g/L blood). 
3.3.4 Statistical analysis 
Results were compared using the 2-tail paired t-test. 
4. RESULTS 
4.1 EVALUATION OF THE YSI 23 AM GLUCOSE ANALYSER FOR GLUCOSE 
MEASUREMENT IN HAEMOLYSATE 
As can be seen in Table 12; using the YSI 23 AM glucose 
analyser/glucose concentrations in fluoridated whole blood and 
haemolysate were not significantly different (p > 0.1) and there 
was excellent agreement between results for whole blood and those 
for haemolysate over a wide range of glucose concentrations (Fig. 
11). An analytical CV of 1.2% was achieved for both. This stand-
ard of performance was even better than the analytical goal (CV ~ 
· 2.2%) proposed by Fraser (52) based on biological variations. 
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Table 12. Comparison of glucose concentration (mmol/L) in whole 
blood (WB) and haemolysate CH) . (mean of each pair of duplicates 
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Fig. 11. Correlation between glucose concentration In haemoly-
sate and whole blood 
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4.2 STABILITY OF GLUCOSE IN HAEMOLYSATE 
The time course of changes in glucose concentration in whole 
blood and haemolysate with and without NaF (2 g/L blood) is 
summarised in Table 13. 
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Table 13. · Comparison of decrease in blood glucose concentration 
(mmol/L) among whole blood and haemolysate samples containing 
fluoride or heparin (mean + SD) (n = 24) 
Time since ... 
collection,h WBH WBF HH HF 
0 5.81 5.80 5.74 5.72 
±2.24 ±2.22 ±2.25 ±2.21 
(3.6-13.4) (3.6-13.2) (3.5-13.3) (3.5-13.2) 
1 0.35 0.35 0.49 0.37 
+0.18 ±0.19 +0.16 ±0.13 
2 0.70 0.53 0.53 0.43 
±0.24 ±O.22 ±0.17 ±0.15 
4 1.24 . 0.50 0.56 . 0.40 
±0.25 ±O . 21 . ±O .18 ±0.13 
8 2.48 0.51 0.52(n=9) 0.41 
±0.31 ±0.15 ±0.17 ±O .14 
24 4.81 0.53 0.57(n=6) 0.33 
±0.88 ±0.15 ±0.29 ±0.27 
Notes .. . Values in the column (1 h or greater) show the differ-
ence from the zero~time mean. 
Range of values given in parentheses. 
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As expected, there was a rapid, continuous decrease of 
glucose with time in heparinised whole blood. The mean loss of 
blood glucose after 1 h of collection at room temperature was 
about 6 %, 12 % after 2 hand 21 % after 4 h. 
For fluoridated whole blood, there was a significant drop of 
~ . 
blood glucose (0.53 mmol/L)2 hafter collection, the main drop 
being in the first hour. The drop of glucose in the first hour 
was not significantly different from heparinised whole blood. 
Thereafter, blood glucose remained stable for at least 24 h. 
This confirmed the previously reported finding by Chan et al (9) 
that NaF has no effect in the first hour and there was a delay of 
at least 2 h before NaF is able to inhibit glycolysis completely. 
Of the heparinised haemolysate samples, 15 had clotted by 8 
hand 18 by 24 h. After an initial drop of 0.54 mmol/L for 2 h, 
glucose concentration in heparinised haemolysate remained stable 
for at least 24 h. 
The mean drop of glucose in fluoridated whole blood was 
significantly less than in heparinised haemolysate 1 h after 
collection (p < 0.01) though the difference was small (0.15 
mmol/L). Thereafter, there was no significant difference between ' 
them for up to 24 H (p > 0.5). 
As for fluoridated haemolysate, there was a significant drop 
of glucose of 0.43 mmol/L in the first 2 h, the main drop being 
in the first hour. Thereafter, it remained stable for at least 
24 h. As with fluoridated whole blood, the drop of glucose in 
the first hour was not significantly different from that of 
heparinised whole blood. 
Comparing the ?tability of glucose concentration in fluori-
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dated haemolysate and fluoridated whole blood, there was no 
significant difference (p = 0.69) in the first hour. Thereafter, 
the drop of qlucose in fluoridated haemolysate was siqnificantly 
less than in fluoridated whole blood (p < 0.05). The mean dif-
ference varied betw~en 0.1 mmol/L to 0.2 mmol/L. 
Comparinq the stability of qlucose concentration in fluori-
dated haemolysate and heparinisedhaemolysate, the loss of qlu-
cose in fluoridated haemolysate was siqnificantly less than in 
heparinised 
0.01). The 
haemolysate for up tq 4 h after collection (p < 
mean difference varied between 0.1 mmol/L to 0.2 
mmol/L with individual data showinq differences of up to 0.5 
mmol/L. After 4 h, there was no siqnificant difference in the 
drop of qlucose between heparinised haemolysate and fluoridated 
haemolysate (p > 0.05). 
The stability ofhaemolysate qlucose concentration in var-
ious concentrations of NaF (2 q/L, 6 q/L and 12 q/L blood respec-
tively) is summarised in Table 14. 
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Table 14. Comparison of decreases in blood glucose concentration 
(mmol/L) among haemolysate samples containing heparin (HH) or 
. different concentration of NaF (HF2, HF6, · HF12) (mean ± SD) · (n 
. = 21) 
Time since 
collection,h HH HF2 HF6 HF12 
0 8.16 8.14 8.23 8.19 
±3.85 ±3.82 ±3.87 .±3.87 
(2.4-18.6) (2.4-18.4) (2.4-18.7) (2.4-18.8) 
1 0.54 0.33 0.45 0.43 
+0.16 +0.11 +0.14 +0.14 
.2 0.57 0.40 0.48 0.45 
. ±O .20 ±O .18 ±0.16 ±0.16 
4 0.56 0.38 0.45 0.39 
±0.20 ±O .11 ±O.lS ±0.15 
8 0.S4(n=11) 0.39 0.43 0.40 
±0.29 ±O .17 ±0.18 ±0.22 
24 0.75(n=2) 0.29 0.32 0.30 
±0.64 ±0.21 ±0.23 ±0.22 
Notes Values in the column (1 h or· greater) show the differ-
ence from zero-time mean. 
Range of values given in parentheses. 
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The general pattern of change of haemolysate glucose concen-
tration in various concentration of NaF was similar. In haemoly-
sate fluoridated with 2 g/L NaF, there was a significant drop of 
glucose concentration of 0.40 mmol/L in the first 2 h after which 
glucose concentration stabilised for at least 24 hwhereas for 
~ . 
NaF concentrations of 6 g/L and 12 g/L blood, after an initial 
. drop of 0.4 - 0.5 mmol/L for 1 h, glucose concentration stabi-
lised for at least 24 h. 
Therefore, increasing the NaF concentration in haemolysate 
did not lead to an improvement in blood glucose preserva~ion by 
abolishing the delay in its action nor did it lessen the drop of 
glucose concentration. 
In fact, the mean drop of haemolysate glucose concentration 
in 2 g/L NaF was significantly less than in 12 g/L NaF during the 
first hour (p < O~Ol) and was significantly less than in 6 g/L 
NaF for up to 4 h (p < 0-.05) after blood collection although the 
difference was very smal1 (up to about 0.1 mmol/L). 
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5. DISCUSSION: 
The results confirmed that haemolysate glucose can be reli-
ably measured in the YSI 23 AM glucose analyser though it has not 
been advocated for such purpose. 
Unlike glucose measured by the hexokinase method in the 
Cobas Mira analyser, there was no interference resulting from 
haemolysis. This might be related to the design of the glucose 
electrode. As mentioned earlier, the glucose probe is covered 
by a 3-layer membrane. The outer layer is a polycarbonate mem-
brane with ~ nominal pore size of 0.03 micrometers which is large 
enough to readily pass glucose, oxygen, hydrogen peroxide, water 
and salt but small enough to exclude cells and to restrict the 
diffusion of enzymes. Thus, potential interferents like haemo-
globin and other interfering macromolecules could not gain access 
to the middle glutaraldehyde resin where glucose oxidase IS 
immobilised. 
Moreover, the results show that freezing is an effective way 
of preserving glucose and is suitable for routine use. This 
technique is attractive because frozen samples can be processed 
as soon as thawing is completed, in a short time, with no sample 
preparation or prior adaptation of the analyser being required. 
For routine practice, the freezing can be achieved by simply 
storing the samples in the freezer compartment of a refrigerator 
at the site of blood collection. Samples can then be transported 
in an ice-box (like samples for blood gas analysis) to the labo-
ratory where further storage in a freezer may be required if 
immediate processing is not possible. The glucose lost before 
analysis will be minimal because it is unlikely that there will 
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be any significant loss when the samples are frozen. As borne 
out by our data, the loss during the process of thawing, if any, 
will be extremely small because the temperature of the sample 
would still be quite low and the delay minimal. 
The major pit~allin the application of freezing as a more 
effective method of processing glucose would be the lack of a 
suitable method for haemolysate analysis in general. Although 
the YSI 23 AM is a good choice, the major drawback is that it 
requires manual sample injection. Therefore, . a fully automated 
analytical system would be preferable. With this in mind an 
attempt was made to develop a hexokinase method in Cobas Mira but 
without success due to matrix effects. Although the matrix 
effect can be alleviated to a certain extent by using calibrants 
of a similar matrix e.g. haemolysate of known glucose concentra-
tion, the haematocrit dependency of the bias of individual sam-
ples would preclude the use of a . constant correction factor. 
However, ~easurement of both haematocrit and haemolysate glucose 
is largely impractical and imprecise particularly when the varia-
bility of the haematocrit dependency is considered. 
Problems related to the analysis of haemolysate glucose in 
general might include hyperviscosity, photometric interference 
and biochemical ·interference. 
Hyperviscosity of the sample 1S a well-documented problem in 
automated systems (54). This problem can be obviated in . manual 
pipettinq because the rate of sample aspiration can be well-
controll~d. That probably explains why hyperviscosity does not 
pose any problem in the YSI 23 AM glucose analyser. 
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In a photometric method, optical interference can be over-
come by suitable blanking. A 'static' blank can be used if the 
blank absorbance does not vary significantly with time whereas a 
'kinetic' blank should be used when the blank changes with time. 
The importance of suitable blanking is best illustrated by 
the interference of saponin. The absorbance of saponin at 340 nm 
could not be corrected for in the hexokinase method because it 
was not until about 2 minutes after the initial absorbance was 
taken that its absorbance at 340 nm stabilised. Nevertheless, a 
kinetic method which measures the rate of change ·of absorbance 
miqht be able to eliminate such interference (55). Besides, 
derivative spectrophotometry (56) and polychromatic analysis (57) 
are potential techniques to eliminate optical interference. 
The negative correlation between the analytical bias and 
haematocrit or haemoglobin was well established in this study. 
In the .. absence of the availability of a purified haemoglobin 
standard, it was not possible to establish their causal relation-
ship in this study. Nevertheless, In a study of the effect of 
interfering substances on results of 11 glucose methods (40), 
which include 7 enzymic methods (3 hexokinase methods, 4 glucose 
oxidase methods), 6 showed negative interference from haemoglobin 
but the mechanism of interference had not been mentioned. The 
hexokinase method which was free from haemoglobin interference, 
is one which involved deproteinisation. 
A major purpose of this study was to ass~ss whether lysis of 
erythrocytes at the time of blood collection would enable NaF to 
act earlier, thereby minimising the decrease in blood glucose 
with storage. This would be clinically useful if confirmed. For 
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instance, it would be possible to prepare sample tubes which 
contain an enzyme inhibitor li~e NaF and a small amount of deter-
gent, both in powder form sufficient to achieve lysis of cells in 
a short period of time. There would be no need for sample dilu-
tion, as required~ in the currently used endpoint or kinetic 
methods of glucose determination for haemolysate (47,49). 
Disappointingly, SDS caused negative interference whereas 
saponin caused positive interference in the hexokinase method. 
As yet, there has not been any published data on the use of such 
detergents in the YSI 23 AM glucose analyser. The limitation of 
time rendered such attempts impractical for this project. Never-
theless, haemolysis effected by 'freeze and thaw' might serve as 
a prototype upon which the effect of NaF can be further explored. 
Previous studies on the er=ectiveness of preserving blood 
glucose by haemolysis involved either a small number of samples 
or covered a short period of time (18,45,46). The results in 
this st~dy confirmed that once the cells are lysed, the glucose 
concentration in haemolysate was stable for at least 24 h after 
an initial drop of about 0.5 mmol/L. 
Although haemolysis confers a preservative effect on blood 
glucose, it is interesting to see that the initial drop (1 h 
after collection) of glucose in heparinised haemolysate was 
significantly higher than in heparinised whole blood. But in the 
presence of NaF, the initial drop of glucose in haemolysate was 
less and was not significantly different from either fluoridated 
whole blood · or heparinised whole blood. This observation was 
further confirmed in the second study. (see Table 14) 
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There are 2 possible implications of these observations. 
Firstly, it appears that haemolysis somehow results in slight 
enhancement of glycelytic loss of glucese in the first heur. 
Secendly, unlike the situation in whele bleed, NaF was taking 
effect in the first hour as a result ef haemelysis theugh its 
antiglycelytic effect was largely incbmplete~ Therefere, a 
combinatien ef haemelysis and NaF preduced 2 cempeting and eppo-
site effects in the first heur. 
The reasen fer an enhanced less ef glucese in haemolysate in 
the first hour when ce.mpared with heparinised whele bleod is not 
clear. To test whether NaF was present in a limiting cO.ncentra-
tien, the second study was pursued. Disappeintingly, increasing 
the concentratien ef NaF in haemelysate did not lead to' an im-
prevement ef bleed glucose preservatien indicating that NaF 
cencentratien ef greater than 2 g/L bloed is not necessary. 
Therefore, the hypathesis that the incemplet~ effect af NaF _ is 
due to' the presence of erythrecyte membrane preventing the imme-
diate entry ef NaF to' bind to' the target enzyme(s) with canse-
quent antiglycelysis cannat be established. 
In a previeus study (27), NaF seemed to' act earlier and glu-
cbse drap in whele blood ~as significantly less with increasing 
cencentrations of NaF. Hewever, similar results were net ab-
tained in this study when haemelysate was used. The reason for 
such discrepancy is net knewn. 
The mechanism fer a time delay in executing the full antig-
lycolytic effect af NaF has yet to' be elucidated. The initial 
action af NaF acts fairly lew in the glycolytic pathway at the 
enelase level (20) and passibly at the pyruvate kinase level as 
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well (58). Consequently, the inhibition of glycolysis is consid-
ered to start at the lower level in the glycolytic pathway and 
then ascend. Furthermore, using human and rat red cells, it has 
been shown that there was a rapid decrease with both the ATP 
level inside the red cells and the activation of phosphofructoki-
nase which is a regulating enzyme of glycolysis (10) . . Therefore, 
a non-instantaneous inhibition of glycolysis might be related to 
these phenomena. It has also been suggested that the metabolism 
of glucose via the pentose phosphate pathway may contribute to 
the early obligatory loss of glucose (5). 
There remains a possibility that enzyme inhibitors which act 
on the early steps of the glycolytic pathway might be more effec-
tive. D-mannose, which acts on the first and third steps of the 
glycolytic pathway, has been reported to be a better antiglyco-
lytic (32). However, the early enthusiasm engendered by the 
findings of Nakashima et al (31) in the use of mannose has re-
cently been tempered (34). On the other hand, citric acid looks 
very promising. By maintaining blood pH at a range of 5.3 -5.9, 
various glycolytic enzymes with hexokinase and phosphofructoki-
nase in particular, are inhibited (41). There is as yet no 
information whether ' other inhibitors like maleinimide(49) may be 
more effective. 
It is concluded that lysis of erythrocytes has a preserva-
tiveeffect on glucose in blood samples. Apart from the initial 
decrease, glucose concentrations in such samples remain 
for at least one day. Addition of NaF resulted in only a 
stable 
slight 
·improvement. NaF is effective but slow in action. The mechanism 
of the apparent delay is not clear and 1S not due to slow pene-
tration into the erythrocytes. The possibility that glycolysis 
can be fully stopped as soon as a blood sample is collected 
remains to be realised. 
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